
TMCI Stock Forecast & Price Target
TMCI Analyst Ratings
Bulls say
Treace Medical Concepts Inc. has observed a 7.0% year-over-year increase in active surgeon users, reaching approximately 3,285, despite a decline in utilization per surgeon, which reflects the company's commitment to expanding its market presence. The potential for improved profit margins is supported by the company’s focus on boosting average selling prices (ASPs) for its products and capturing a larger share of complementary foot and ankle procedures. With an enhanced sales force driving growth and the opportunity for ancillary product sales to contribute to revenue, Treace Medical Concepts is positioned for sustainable revenue growth in the coming years.
Bears say
Treace Medical Concepts Inc. is experiencing a projected revenue decline of approximately 10% year-over-year for the fourth quarter, which is typically characterized as the "bunion season." The company's revenue guidance for fiscal year 2025 has been reduced to a range of $211-213 million, down from a prior estimate of $224-230 million, largely due to weaker elective procedure volumes and specific headwinds related to their Lapiplasty procedure. Furthermore, estimates indicate negative year-over-year growth for 2026, contributing to an expectation of the company's valuation multiple remaining flat or declining due to continued market challenges.
This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.
TMCI Analyst Forecast & Price Prediction
Start investing in TMCI
Order type
Buy in
Order amount
Est. shares
0 shares